| **Quality assessment** | **№ of patients** | **Effect** | **Quality** | **Importance** |
| --- | --- | --- | --- | --- |
| **№ of studies** | **Study design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **Selective cannabinoids** | **Placebo / conventional treatment** | **Relative(95% CI)** | **Absolute(95% CI)** |
| Analgesic efficacy of cannabinoids on neuropathic pain (all types) (assessed with numerical rating scores on a 0-10 scale) |
| 10  | randomised trials  | not serious  | serious 1 | not serious  | not serious  | none  | 486  | 487  | -  | MD **0.65 lower**(1.06 lower to 0.23 lower)  | ⨁⨁⨁◯MODERATE  | IMPORTANT  |
| Analgesic efficacy of cannabinoids on central neuropathic pain (assessed with numerical rating scores on a 0-10 scale) |
| 5  | randomised trials  | not serious  | serious 2 | not serious  | not serious  | none  | 281  | 283  | -  | MD **0.73 lower**(1.26 lower to 0.2 lower)  | ⨁⨁⨁◯MODERATE  | IMPORTANT  |
| Analgesic efficacy of cannabinoids on peripheral neuropathic pain (assessed with numerical rating scores on a 0-10 scale) |
| 3  | randomised trials  | serious 3 | serious 4 | not serious  | not serious  | none  | 91  | 90  | -  | MD **0.72 lower**(2.04 lower to 0.59 higher)  | ⨁⨁◯◯LOW  | IMPORTANT  |

**Supplemental Table 3.** GRADE Evidence Profile: Selective cannabinoids as adjunct analgesics in neuropathic pain.

**CI:** Confidence interval; **MD:** Mean difference

1. Five of 11 trials did not demonstrate significant analgesic benefit for selective cannabinoid use
2. Three of 5 trials did not demonstrate significant analgesic benefit for selective cannabinoid use
3. One trial deemed to have a high risk of bias did not adequately describe the procedure for generation of randomization, concealment of allocation, and blinding of participants
4. One of 3 trials did not demonstrate significant analgesic benefit for selective cannabinoid use